Printed From:

Healthcare professionals have chosen Lantus® for over 18 years1


Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure.

CV Evaluation from the ORIGIN Trial over 6.2 Years (N=12,537)

No statistically significant differences between Lantus® and standard care in the co-primary endpoints

Mean A1C over 6.2 years (median)

Safety results

Study Design

A randomized study of patients with IFG and/or IGT or early type 2 diabetes mellitus and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed at the discretion of the investigator. The co-primary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. Median follow-up: 6.2 years.

*Eligibility Restrictions

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. Important to note that if you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law.

Savings may vary depending on patients' out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.

Offer Terms for Lantus $0 Co-pay Savings Card

For the duration of the program, the Savings Card offers a $0 copay with a maximum savings up to $600 per box for prescriptions covered by private or commercial insurance. This offer is valid for up to 3 boxes per prescription.

Offer Terms for Insulins Valyou Savings Program ($99)

Sanofi insulins included in this program are: LANTUS® (insulin glargine injection) 100 Units/mL, TOUJEO® (insulin glargine injection) 300 Units/mL, ADMELOG® (insulin lispro injection) and APIDRA® (insulin glulisine injection) 100 Units/mL

This offer is not valid for prescriptions covered by commercial / private insurance. Only people without prescription medication insurance can apply for this offer. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of pens per fill. Offer is valid for one fill per month. In order for you to pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. This offer is not valid for the Max SoloStar pen. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.